Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tuberculosis | Research

Complete sputum smear monitoring among adults with pulmonary tuberculosis in central Uganda: evidence from a retrospective cohort study

Authors: Ronald Nsubuga, Norbert Adrawa, Stephen Okoboi, Alimah Komuhangi, Jonathan Izudi

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

People with bacteriologically confirmed pulmonary tuberculosis require sputum smear monitoring at 2, 5, and 6 months to establish treatment outcomes. However, there is limited information about sputum smear monitoring in Uganda, similar to other developing countries. We examined factors associated with complete sputum smear monitoring among persons with bacteriologically confirmed pulmonary TB aged ≥ 15 years in central Uganda.

Methods

We retrospectively reviewed and abstracted data for persons with bacteriologically confirmed pulmonary TB initiated on treatment between January 2017 and December 2019 across 11 large TB units in Masaka district in central Uganda. Complete sputum smear monitoring was measured as the receipt of three sputum smear microscopy tests at 2, 5, and 6 months of TB treatment. The data were summarized descriptively and the differences in the outcome with independent variables were examined using tests of statistical significance, namely the Chi-square or Fisher’s exact test and the student’s t-test. The factors independently associated with the outcome were established using the modified Poisson regression analysis with robust standard errors, reported as adjusted risk ratio (aRR) along with the 95% confidence interval (CI).

Results

A total of 416 participants were enrolled, with a mean age of 37.3 ± 12.9 years. Of the participants, 290 (69.7) were males, 269 (64.7) were rural residents, and 128 (30.8%) had complete sputum smear monitoring. Urban residence (aRR, 1.45; 95% CI 1.12–1.90) and treatment under the community-based directly observed therapy short-course strategy (DOTS) (aRR, 1.91; 95% CI 1.25–2.92) were associated with a higher likelihood of complete sputum smear monitoring while TB and human immunodeficiency virus (TB/HIV) comorbidity (aRR 0.45, 95% CI 0.30–0.68) was associated with a lower likelihood of complete sputum smear monitoring.

Conclusions

We found a low magnitude of complete sputum smear monitoring among persons with bacteriologically confirmed pulmonary TB aged ≥ 15 years in central Uganda. Strategies to enhance the performance of sputum smear monitoring should target rural health facilities, strengthen TB/HIV collaboration and the implementation of community-based DOTS.
Literature
1.
go back to reference World Health Organization. Global tuberculosis report 2021. Geneva: Switzerland; 2021. World Health Organization. Global tuberculosis report 2021. Geneva: Switzerland; 2021.
2.
go back to reference Republic of Uganda. National Tuberculosis and Leprosy Control Program: Revised National Strategic Plan 2015/16–2019/20. Kampala, Uganda: Ministry of Health, 2017. Republic of Uganda. National Tuberculosis and Leprosy Control Program: Revised National Strategic Plan 2015/16–2019/20. Kampala, Uganda: Ministry of Health, 2017.
3.
go back to reference World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017.
4.
go back to reference Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006;6(11):710–25.CrossRef Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006;6(11):710–25.CrossRef
5.
go back to reference Republic of Uganda. National Tuberculosis and Leprosy Control Program: Revised National Strategic Plan 2015/16–2019/20. Kampala, Uganda; 2017. Republic of Uganda. National Tuberculosis and Leprosy Control Program: Revised National Strategic Plan 2015/16–2019/20. Kampala, Uganda; 2017.
6.
go back to reference Republic of Uganda. Annual health sector performance report: financial year 2019/2020. Kampala, Uganda: Ministry of Health, Uganda; 2020. Republic of Uganda. Annual health sector performance report: financial year 2019/2020. Kampala, Uganda: Ministry of Health, Uganda; 2020.
7.
go back to reference World Health Organization. Treatment of tuberculosis: guidelines for nationl programmes: World Health Organization; 2003. World Health Organization. Treatment of tuberculosis: guidelines for nationl programmes: World Health Organization; 2003.
8.
go back to reference Izudi J, Tamwesigire IK, Bajunirwe F. Does completion of sputum smear monitoring have an effect on treatment success and cure rate among adult tuberculosis patients in rural Eastern Uganda? A propensity score-matched analysis. PloS one. 2019;14(12):e0226919.CrossRef Izudi J, Tamwesigire IK, Bajunirwe F. Does completion of sputum smear monitoring have an effect on treatment success and cure rate among adult tuberculosis patients in rural Eastern Uganda? A propensity score-matched analysis. PloS one. 2019;14(12):e0226919.CrossRef
9.
go back to reference Izudi J, Tamwesigire IK, Bajunirwe F. Treatment supporters and level of health facility influence completion of sputum smear monitoring among tuberculosis patients in rural Uganda: a mixed-methods study. Int J Infect Dis. 2020;91:149–55.CrossRef Izudi J, Tamwesigire IK, Bajunirwe F. Treatment supporters and level of health facility influence completion of sputum smear monitoring among tuberculosis patients in rural Uganda: a mixed-methods study. Int J Infect Dis. 2020;91:149–55.CrossRef
10.
go back to reference Harries A, Gausi F, Salaniponi F. When are follow-up sputum smears actually examined in patients treated for new smear-positive pulmonary tuberculosis? Int J Tuberc Lung Dis. 2004;8(4):440–4.PubMed Harries A, Gausi F, Salaniponi F. When are follow-up sputum smears actually examined in patients treated for new smear-positive pulmonary tuberculosis? Int J Tuberc Lung Dis. 2004;8(4):440–4.PubMed
11.
go back to reference Nakaggwa P, Odeke R, Kirenga B, Bloss E. Incomplete sputum smear microscopy monitoring among smear-positive tuberculosis patients in Uganda. Int J Tuberc Lung Dis. 2016;20(5):594–9.CrossRef Nakaggwa P, Odeke R, Kirenga B, Bloss E. Incomplete sputum smear microscopy monitoring among smear-positive tuberculosis patients in Uganda. Int J Tuberc Lung Dis. 2016;20(5):594–9.CrossRef
12.
go back to reference Kayigamba FR, Bakker MI, Mugisha V, Gasana M, van der Loeff MFS. Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program. BMC Res Notes. 2012;5(1):1–7.CrossRef Kayigamba FR, Bakker MI, Mugisha V, Gasana M, van der Loeff MFS. Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program. BMC Res Notes. 2012;5(1):1–7.CrossRef
13.
go back to reference Javira S. Massive! Uganda's health sector delivering service with confidence as citizens reap from infrastructure investiment (Part II). 2020. Javira S. Massive! Uganda's health sector delivering service with confidence as citizens reap from infrastructure investiment (Part II). 2020.
15.
go back to reference Lauritsen J. EpiData (version 3.1). A comprehensive tool for validated entry and documentation of data. 2004. Lauritsen J. EpiData (version 3.1). A comprehensive tool for validated entry and documentation of data. 2004.
16.
go back to reference Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health. 2008;53(3):165.CrossRef Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health. 2008;53(3):165.CrossRef
17.
go back to reference Cameron AC, Trivedi PK. Regression-based tests for overdispersion in the Poisson model. J Econometrics. 1990;46(3):347–64.CrossRef Cameron AC, Trivedi PK. Regression-based tests for overdispersion in the Poisson model. J Econometrics. 1990;46(3):347–64.CrossRef
18.
go back to reference Attia A. Why should researchers report the confidence interval in modern research. Middle East Fertil Soc J. 2005;10(1):78–81. Attia A. Why should researchers report the confidence interval in modern research. Middle East Fertil Soc J. 2005;10(1):78–81.
19.
go back to reference Gupta SK. The relevance of confidence interval and P-value in inferential statistics. Indian J Pharmacol. 2012;44(1):143.CrossRef Gupta SK. The relevance of confidence interval and P-value in inferential statistics. Indian J Pharmacol. 2012;44(1):143.CrossRef
20.
go back to reference Akobeng AK. Confidence intervals and p-values in clinical decision making. Acta Paediatr. 2008;97(8):1004–7.CrossRef Akobeng AK. Confidence intervals and p-values in clinical decision making. Acta Paediatr. 2008;97(8):1004–7.CrossRef
21.
go back to reference Ranstam J. Why the P-value culture is bad and confidence intervals a better alternative. Elsevier; 2012. Ranstam J. Why the P-value culture is bad and confidence intervals a better alternative. Elsevier; 2012.
22.
go back to reference Halsey LG. The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum? Biol Let. 2019;15(5):20190174.CrossRef Halsey LG. The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum? Biol Let. 2019;15(5):20190174.CrossRef
24.
go back to reference Izudi J, Semakula D, Sennono R, Tamwesigire IK, Bajunirwe F. Treatment success rate among adult pulmonary tuberculosis patients in sub-Saharan Africa: a systematic review and meta-analysis. BMJ Open. 2019;9(9):e029400.CrossRef Izudi J, Semakula D, Sennono R, Tamwesigire IK, Bajunirwe F. Treatment success rate among adult pulmonary tuberculosis patients in sub-Saharan Africa: a systematic review and meta-analysis. BMJ Open. 2019;9(9):e029400.CrossRef
25.
go back to reference Musaazi J, Kiragga A, Castelnuovo B, Kambugu A, Bradley J, Rehman A. Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study. Public health action. 2017;7(2):100–9.CrossRef Musaazi J, Kiragga A, Castelnuovo B, Kambugu A, Bradley J, Rehman A. Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study. Public health action. 2017;7(2):100–9.CrossRef
26.
go back to reference Tadesse T, Demissie M, Berhane Y, Kebede Y, Abebe M. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424.CrossRef Tadesse T, Demissie M, Berhane Y, Kebede Y, Abebe M. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424.CrossRef
27.
go back to reference Republic of Uganda. Health Sector Development Plan 2015/16–2019/2020. Kampala, Uganda: Ministry of Health, 2015. Republic of Uganda. Health Sector Development Plan 2015/16–2019/2020. Kampala, Uganda: Ministry of Health, 2015.
28.
go back to reference Republic of Uganda. Annual health sector performance report: financial year 2017/2018. Kampala, Uganda: Ministry of Health, Uganda; 2018. Republic of Uganda. Annual health sector performance report: financial year 2017/2018. Kampala, Uganda: Ministry of Health, Uganda; 2018.
29.
go back to reference World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis: World Health Organization; 2014. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis: World Health Organization; 2014.
30.
go back to reference Wright CM, Westerkamp L, Korver S, Dobler CC. Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness. BMC Infect Dis. 2015;15:210.CrossRef Wright CM, Westerkamp L, Korver S, Dobler CC. Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness. BMC Infect Dis. 2015;15:210.CrossRef
31.
go back to reference Zhang H, Ehiri J, Yang H, Tang S, Li Y. Impact of community-based dot on tuberculosis treatment outcomes: a systematic review and meta-analysis. PloS One. 2016;11(2):e0147744.CrossRef Zhang H, Ehiri J, Yang H, Tang S, Li Y. Impact of community-based dot on tuberculosis treatment outcomes: a systematic review and meta-analysis. PloS One. 2016;11(2):e0147744.CrossRef
32.
go back to reference Mafigiri DK, McGrath JW, Whalen CC. Task shifting for tuberculosis control: a qualitative study of community-based directly observed therapy in urban Uganda. Glob Public Health. 2012;7(3):270–84.CrossRef Mafigiri DK, McGrath JW, Whalen CC. Task shifting for tuberculosis control: a qualitative study of community-based directly observed therapy in urban Uganda. Glob Public Health. 2012;7(3):270–84.CrossRef
33.
go back to reference Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10(1):1–9.CrossRef Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10(1):1–9.CrossRef
34.
go back to reference Daftary A, Padayatchi N. Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care. 2012;24(12):1480–6.CrossRef Daftary A, Padayatchi N. Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care. 2012;24(12):1480–6.CrossRef
Metadata
Title
Complete sputum smear monitoring among adults with pulmonary tuberculosis in central Uganda: evidence from a retrospective cohort study
Authors
Ronald Nsubuga
Norbert Adrawa
Stephen Okoboi
Alimah Komuhangi
Jonathan Izudi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07178-9

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue